Tiziana Life Sciences Announces Positive Topline Data from Phase 2a INFORM-MS Trial

Tiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis. The trial met its dual primary endpoints, with the 50 μg dose producing a statistically significant reduction in microglial activation on TSPO PET imaging versus placebo and showing a favorable safety and tolerability profile. The 100 μg dose was also well tolerated but did not achieve a statistically significant reduction in neuroinflammation; the report did not provide financial results or a stock-price impact.